Berenberg Bank Lowers AstraZeneca plc (AZN) Price Target to GBX 5,500
AstraZeneca plc (LON:AZN) had its price target decreased by equities researchers at Berenberg Bank from GBX 5,550 ($69.34) to GBX 5,500 ($68.72) in a research report issued to clients and investors on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Berenberg Bank’s price objective indicates a potential upside of 27.21% from the stock’s previous close.
Several other analysts have also issued reports on the company. Societe Generale reissued a “buy” rating and set a GBX 6,500 ($81.21) price target on shares of AstraZeneca plc in a report on Wednesday, November 16th. BNP Paribas reaffirmed a “neutral” rating and issued a GBX 5,100 ($63.72) price objective on shares of AstraZeneca plc in a research note on Monday, November 14th. Goldman Sachs Group Inc. set a GBX 4,000 ($49.98) price objective on AstraZeneca plc and gave the stock a “sell” rating in a research note on Friday, November 11th. HSBC reaffirmed a “hold” rating and issued a GBX 4,700 ($58.72) price objective on shares of AstraZeneca plc in a research note on Friday, November 11th. Finally, JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of AstraZeneca plc in a research note on Friday, November 11th. Four analysts have rated the stock with a sell rating, fourteen have given a hold rating, ten have assigned a buy rating and one has issued a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of GBX 4,974.56 ($62.15).
AstraZeneca plc (LON:AZN) opened at 4323.5000 on Thursday. The company’s market capitalization is GBX 54.69 billion. The company’s 50-day moving average price is GBX 4,725.10 and its 200 day moving average price is GBX 4,569.59. AstraZeneca plc has a 52-week low of GBX 3,680.00 and a 52-week high of GBX 5,505.00.
About AstraZeneca plc
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Stock Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related stocks with our FREE daily email newsletter.